Trial Profile
A retrospective, multicenter study of eribulin mesylate in patients with locally advanced or metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ERIBEX
- 22 Jul 2016 New trial record.